Utility and optimal dose of nicorandil for physiological assessment of the femoropopliteal artery
© 2024 Wiley Periodicals LLC..
BACKGROUND: Nicorandil is widely used as a vasodilator for the physiological assessment of coronary arteries because of its usefulness and safety; however, there are no data on its use in peripheral arteries.
AIMS: To identify the utility of nicorandil and its appropriate dose for the physiological assessment on the femoropopliteal artery.
METHODS: We retrospectively enrolled patients from three institutes in which physiological assessment was carried out with various doses of nicorandil before treatment. Twenty-four femoropopliteal artery stenotic lesions from 22 patients were included. The nicorandil doses used were 2, 4, and 6 mg. Twenty-two lesions were also assessed using 30 mg of papaverine. The pressure gradient (PG) and peripheral fractional flow reserve (pFFR) were calculated based on the mean and systolic pressure levels. We examined the correlation of each parameter with the peak systolic velocity ratio (PSVR) based on the duplex ultrasound images using Spearman's rank correlation coefficient. Systemic blood pressure was assessed for safety.
RESULTS: The correlations were higher for mean pressure-based parameters than for systolic pressure-based parameters. As the nicorandil dose increased, the correlations among PG, pFFR, and PSVR also increased (mean pressure-based PG: 2 mg, r = 0.360; 4 mg, r = 0.498; 6 mg, r = 0.694, mean pressure-based pFFR: 2 mg, r = -0.479; 4 mg, r = -0.469; 6 mg, r = -0.641). The blood pressure after the administration of 6 mg of nicorandil was low, and the median systemic mean pressure was 65 mmHg.
CONCLUSION: A 4 mg dose of nicorandil is effective and safe for the mean pressure-based physiological assessment of lesions in the femoropopliteal artery.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:103 |
|---|---|
| Enthalten in: |
Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions - 103(2024), 4 vom: 15. März, Seite 670-677 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Yoshioka, Naoki [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
260456HAM0 |
|---|
| Anmerkungen: |
Date Completed 19.03.2024 Date Revised 21.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1002/ccd.30976 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM368531201 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM368531201 | ||
| 003 | DE-627 | ||
| 005 | 20240323000802.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240216s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/ccd.30976 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1341.xml |
| 035 | |a (DE-627)NLM368531201 | ||
| 035 | |a (NLM)38363043 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Yoshioka, Naoki |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Utility and optimal dose of nicorandil for physiological assessment of the femoropopliteal artery |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 19.03.2024 | ||
| 500 | |a Date Revised 21.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024 Wiley Periodicals LLC. | ||
| 520 | |a BACKGROUND: Nicorandil is widely used as a vasodilator for the physiological assessment of coronary arteries because of its usefulness and safety; however, there are no data on its use in peripheral arteries | ||
| 520 | |a AIMS: To identify the utility of nicorandil and its appropriate dose for the physiological assessment on the femoropopliteal artery | ||
| 520 | |a METHODS: We retrospectively enrolled patients from three institutes in which physiological assessment was carried out with various doses of nicorandil before treatment. Twenty-four femoropopliteal artery stenotic lesions from 22 patients were included. The nicorandil doses used were 2, 4, and 6 mg. Twenty-two lesions were also assessed using 30 mg of papaverine. The pressure gradient (PG) and peripheral fractional flow reserve (pFFR) were calculated based on the mean and systolic pressure levels. We examined the correlation of each parameter with the peak systolic velocity ratio (PSVR) based on the duplex ultrasound images using Spearman's rank correlation coefficient. Systemic blood pressure was assessed for safety | ||
| 520 | |a RESULTS: The correlations were higher for mean pressure-based parameters than for systolic pressure-based parameters. As the nicorandil dose increased, the correlations among PG, pFFR, and PSVR also increased (mean pressure-based PG: 2 mg, r = 0.360; 4 mg, r = 0.498; 6 mg, r = 0.694, mean pressure-based pFFR: 2 mg, r = -0.479; 4 mg, r = -0.469; 6 mg, r = -0.641). The blood pressure after the administration of 6 mg of nicorandil was low, and the median systemic mean pressure was 65 mmHg | ||
| 520 | |a CONCLUSION: A 4 mg dose of nicorandil is effective and safe for the mean pressure-based physiological assessment of lesions in the femoropopliteal artery | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a fractional flow reserve | |
| 650 | 4 | |a nicorandil | |
| 650 | 4 | |a peak systolic velocity ratio | |
| 650 | 4 | |a peripheral artery disease | |
| 650 | 4 | |a physiology | |
| 650 | 4 | |a pressure gradient | |
| 650 | 7 | |a Nicorandil |2 NLM | |
| 650 | 7 | |a 260456HAM0 |2 NLM | |
| 650 | 7 | |a Vasodilator Agents |2 NLM | |
| 700 | 1 | |a Shimada, Takenobu |e verfasserin |4 aut | |
| 700 | 1 | |a Iwasaki, Yoshihiro |e verfasserin |4 aut | |
| 700 | 1 | |a Yoshida, Hisako |e verfasserin |4 aut | |
| 700 | 1 | |a Otsuka, Kenichiro |e verfasserin |4 aut | |
| 700 | 1 | |a Yamazaki, Takanori |e verfasserin |4 aut | |
| 700 | 1 | |a Morita, Yasuhiro |e verfasserin |4 aut | |
| 700 | 1 | |a Nakamura, Shigeru |e verfasserin |4 aut | |
| 700 | 1 | |a Fukuda, Daiju |e verfasserin |4 aut | |
| 700 | 1 | |a Morishima, Itsuro |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions |d 1999 |g 103(2024), 4 vom: 15. März, Seite 670-677 |w (DE-627)NLM101487487 |x 1522-726X |7 nnns |
| 773 | 1 | 8 | |g volume:103 |g year:2024 |g number:4 |g day:15 |g month:03 |g pages:670-677 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/ccd.30976 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 103 |j 2024 |e 4 |b 15 |c 03 |h 670-677 | ||